|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| bioLOGIC 2002 - Terrapinn | ||||||||||||||||
| April 22, 2002 | ||||||||||||||||
|
bioLOGIC 2002, President Wilson Hotel, Geneva 5th - 7th June 2002 http://www.pharma-rd.net/biologic2002/index.asp The Conference Programme Day One / Two / Three Day one - 5th June 2002 8.30 Registration 9:00 Chairperson's opening remarks Monica Darnbrough, Director for Biotechnology, Chemicals & Biotechnology Directorate, DTI Integrating capacity, demand and out-sourcing strategies 9:10 Keynote Presentation: Dr Gerben Algra, President & CEO, DSM Biologics 9:40 Critical factors for big pharma in considering out-sourcing Dr Joseph Villafranca, Vice-President, Biologics Strategy & Operations, Bristol Myers Squibb 10:20 Morning coffee and exhibition viewing 11:00 Developing an integrated flexible manufacturing strategy Mark Bamforth, Senior Vice-President, Corporate Operations, Genzyme Corporation 11:30 Panel session: Feeling the squeeze? How to develop an integrated capacity strategy Dr Gerben Algra, President & CEO, DSM Biologics Dr Joseph Villafranca, Vice-President, Biologics Strategy & Operations, Bristol Myers Squibb Mark Bamforth, Senior Vice-President, Corporate Operations, Genzyme Corporation Dr Paul Coleman, Vice-President of Manufacturing and General Manager, Denmark, Biogen Denmark Sandra Fox, President, HighTech Business Decisions 12:30 How to gain a competitive position in an industry faced with capacity crisis Dr Suzanne Griffiths, Senior Consultant, Pharmaceuticals & Biotechnology, Wood Mackenzie 1:00 Lunch sponsored by Wood Mackenzie 2:30 Site selection and construction for a flexible manufacturing strategy Dr Paul Coleman, Vice-President of Manufacturing and General Manager, Denmark, Biogen Denmark 3:10 Panel session: Exploring regional initiatives in Europe for cost-effective manufacturing Joachim Steen Mikkelsen, Business Development Manager, Copenhagen Capacity Liam Fennell, Biotechnology Team Leader, Scottish Enterprise 4:15 Break Scale-up challenges 5:00 Challenges in the manufacturing of large volume biotech products Dr Alain Bernard, Director, Recombinant Bulk Manufacturing, Serono Biotech Center 5:30 Strategy for expansion of manufacturing capacity for a mammalian cell derived product to support a market growth strategy Inger Mollerup, Vice President, Protein Process Development, Novo Nordisk A/S Structuring investment for growth 6:00 Creative financing for raising funding for manufacturing facilities 6:30 Close of conference Day two - 6th June 2002 9:00 Chairperson's opening remarks Planning and managing cost-effective manufacturing operations 9:10 Keynote Presentation Achieving competitive advantage through process development Parrish Galliher, Vice-President of Biologics Manufacturing, Millennium Pharmaceuticals, Inc. (USA) 9:40 Keys to successful technology transfer and validation in out-sourcing John C. McPherson, Director of Validation, Immunex Corporation 10:20 Morning coffee and exhibition viewing 11:00 Managing multi-sourced biotechnology product manufacturing facilities in South East Asia Martin Comberbach, Director of Global Manufacturing, Genemedix 11:40 Process optimisation and novel techniques to intensify downstream processing Charles Christy, Biotechnology Market Director, Millipore 12:20 Lunch Building and managing partnerships for future growth 2:20 Selecting a preferred provider/partner for a successful outsourcing of R&D Dr Makarand Jawadekar, Assistant Director, Pharmaceutical Science Operations & Strategic External Alliance Management Pfizer Global R & D 3:00 Panel session: How biotech and pharma convergence will change manufacturing Parrish Galliher, Head of Biologics Manufacturing, Millennium Pharmaceuticals, Inc. (USA) Dr Makarand Jawadekar, Assistant Director, Pharmaceutical Science Operations & Strategic External Alliance Management, Pfizer Global R & D Sharon Redmond, Head of Biologicals Manufacturing Development, Celltech Group Dr Joseph Santangelo, Associate Director, Process Formulation & Development, Microscience 4:00 Break 4:40 Selecting a CMO: from a CMO’s perspective * Andy Lewin, Business Development Director, Accentus Biologics 5:20 Outsourcing product development and manufacturing for biologicals: Experiences of a small biotech company Dr Joseph Santangelo, Associate Director, Process Formulation & Development, Microscience 6:00 Close of conference Day three - 7th June 2002 9:00 Chairperson’s opening remarks Sandra Fox, President, HighTech Business Decisions 9:10 Keynote Presentation Biopharmaceuticals outsourcing: Is there a business model that is workable and flexible? Professor Rolf Werner, Head of Corporate Division Biopharmaceuticals, Boehringer Ingelheim Managing regulatory, characterisation and validation issues, reducing time-to-market 9:40 Directives and annexes -an overview of implications for European exporting and manufacturing development Dr Lincoln Tsang, Head of Biologicals and Biotechnology, Medicines Control Agency 10:20 Understanding US regulations and their impact on manufacturing development in Europe Dr Theresa Finn, Scientific Reviewer, Office of Vaccines In Research and Review, CBER, FDA 11:00 Morning coffee and exhibition viewing 11:45 Strategic use of (bio-) assays during the development of biopharmaceuticals Dr Hans-Joachim Wallny, BTD Bioanalytics, Head of Bioassay Group, Novartis Pharma AG 12:15 Comparability issues in the development of biotechnology products Dr Meena Wadhwa, Principal Scientist, National Institute for Biological Standards & Control 12:45 Lunch Improving yield with new technologies -challenges and possibilities 2:40 Transgenic milk production platform update Philip Onigman, Director of Marketing, Genzyme Transgenics 3:20 Case study: Potential cost benefits to protein production from Q-cells Dr Joe Carey, Senior Licensing Executive, British Technology Group 4:00 Close of conference |
||||||||||||||||
| Organized by: | Terrapinn Ltd | |||||||||||||||
| Invited Speakers: | * Dr Gerben Algra, President & CEO, DSM Biologics * Parrish Galliher, Vice-President of Biologics Manufacturing, Millennium Pharmaceuticals, Inc. (USA) * Dr Makarand Jawadekar, Assistant Director, Pharmaceutical Science Operations & Strategic External Alliance Management, Pfizer Global R&D * Dr Joseph Villafranca, Vice-President, Biologics Strategy & Operations, Bristol Myers Squibb * Dr Teresa Finn, Scientific Reviewer, CBER, FDA * Dr Alain Bernard, Director, Recombinant Bulk Manufacturing, Serono Biotech Center * Dr Hans-Joachim Wallny, Head of Bioassay Development, Novartis Pharma AG * Andy Lewin, Business Development Director, Biologics, Accentus Plc. * Andy Lewin, Business Development Director, Accentus Biologics * Dr Meena Wadhwa, Principal Scientist, National Institute for Biological Standards & Control * Dr Lincoln Tsang, Head of Biologicals and Biotechnology, Medicines Control Agency |
|||||||||||||||
| Deadline for Abstracts: | N/A | |||||||||||||||
| Registration: | bioLOGIC 2002 conference: 5th - 7th June 2002 All three days £1695 4 easy ways to register: Phone: +44 (0)20 7242 2324 Fax: +44 (0)20 7242 2320 On-line: http://www.pharma-rd.net/biologic2002/register.asp Post: Terrapinn, 2nd Floor, 100 Hatton Garden, London EC1N 8NX, UK For further information on this event, please contact Danny Grogan on +44 (0)20 7827 5983 or email danny.grogan@terrapinn.com |
|||||||||||||||
| E-mail: | danny.grogan@terrapinn.com | |||||||||||||||
| Posted by: | Heather Ward | |||||||||||||||
| Host: | 213.205.146.137 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||